MAM
Suneet Manchanda joins Mogae as COO
MUMBAI: Mogae Media has got on board Suneet Manchanda as its COO for deals and delights. He will be based at the company‘s Gurgaon headquarters and shall report to chief value officer Rajendra Gupta.
Gupta joined a few months ago from Reliance ADA Group.
Mogae Media executive director Tanya Goyal said, “Suneet has rich experience in eCommerce space and is one of the few individuals who has built some of the best known ecommerce businesses from scratch in India. He has played pivotal role in creating and managing businesses at Indiatimes, Sify, Tradus and Ladyblush. He possesses great understanding of key business processes and has worked with a wide range of businesses in leadership roles.”
Prior to joining Mogae, Manchanda co-founded the women-only shopping website Ladyblush and took care of technology, merchant acquisitions and alliances. He continues to be an investor in the company. Before becoming an entrepreneur, he was VP and business head for Tradus which is an Ibibo venture where he spent four years and built the eCommerce business from scratch.
Manchanda started his carrier with Times FM, the radio business of BCCL in sales in the year 1996 before moving to Times Internet Ltd in 1999 where he launched Indiatimes Shopping. After Indiatimes, he moved on to head business development and operations for Sifymall, an ecommerce venture of Sify.
Brands
Bayer sues Johnson & Johnson over prostate cancer drug advertisements
Legal dispute begins as Bayer claims rival marketing is based on flawed data
NEW YORK: Bayer has filed a federal lawsuit against Johnson & Johnson (J&J) in New York, alleging that the American pharmaceutical company has used false and misleading advertisements to promote its prostate cancer treatment, Erleada. The dispute centres on claims that Erleada is significantly more effective than Bayer’s competing drug, Nubeqa.
The legal action follows a J&J marketing campaign that cited a 51 per cent reduction in the risk of death for patients using Erleada compared to those on Nubeqa. Bayer contends that these figures are based on a study with severe methodological errors rather than a controlled clinical trial.
Bayer’s legal team argues that J&J’s real-world analysis is fundamentally flawed. According to the complaint, J&J claimed to have 24 months of patient data supporting its conclusions, even though many patients included in the study had reportedly been on the medication for only a few months, raising concerns about the reliability of long-term survival comparisons.
The lawsuit also highlights what Bayer describes as a critical approval gap. For most of the period analysed in J&J’s study, Nubeqa had not yet been approved for the specific indication being evaluated, which Bayer argues makes a direct clinical comparison inappropriate and potentially misleading.
Additionally, Bayer contends that the study suffered from significant sample imbalance. The analysis reportedly included five times as many Erleada patients as Nubeqa patients, a disparity that Bayer says introduced statistical bias and undermined the validity of the findings.
Bayer is pursuing the case under the Lanham Act, the U.S. law governing false advertising and unfair competition. The company is seeking an immediate halt to J&J’s current marketing campaign and is asking the court to require corrective statements to physicians to address what it characterises as inaccurate claims.
Furthermore, Bayer is seeking monetary damages, arguing that the alleged misleading advertisements have resulted in lost revenue and reputational harm to Nubeqa.
Johnson & Johnson has responded by stating that it stands by the integrity of its data and the rigour of its analysis. The case will now proceed through the U.S. District Court for the Southern District of New York.
